Skip to Main Content

An official website of the United States government

BMI and Impact on Screening for Prostate Cancer

Principal Investigator
Name
Robert Grubb
Institution
Washington University School of Medicine in St. Louis
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2006-0034
Initial CDAS Request Approval
Jul 1, 2006
Title
BMI and Impact on Screening for Prostate Cancer
Summary
Other investigators have previously shown that increasing BMI is a potential risk factor for increased mortality from a number of cancers, including prostate cancer. Further, it has been shown that there is an inverse relationship between serum PSA and BMI. Additional investigations have shown a potential for worse outcomes among obese men diagnosed with prostate cancer. The results of these single institution and epidemiologic studies have not been consistent. The exact relationships between BMI and serum PSA levels and prostate cancer incidence and aggressiveness have not been established. We seek to use data from the PLCO Cancer screening trial to further elucidate the relationship between BMI and serum PSA and prostate cancer diagnosis and prostate cancer aggressiveness.
Aims

Based on the findings of other investigators as outlined above, we propose to perform an in-depth study of the relationship of BMI and serum PSA levels among men without prostate cancer in the PLCO cancer screening trial We will then examine the impact of increasing BMI on the incidence of prostate cancer among men who had undergone biopsies. We will also examine the incidence of aggressive cancers as determined by biopsy Gleason score.

Collaborators

Amanda Black (Division of Cancer Prevention)

Related Publications